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Abstract
Background: Systematic reviews (SRs) form the foundation for guidelines and evidence-based policy in medicine and
public health. Although similar systematic reviews may include non-identical sets of studies, and it is recognized that
different sets of studies may lead to different conclusions, little work has been published on why SR study cohorts
differ.
Methods: We took advantage of concurrent publication of two SRs on the same topic – prevention of child exposure
to tobacco smoke - to understand why study cohorts differed in the two reviews. We identified all studies included in
just one review, investigated validity of specified reasons for exclusions, and, using database records, explored reasons
for study non-identification. We assessed review methods and discordancy, and attempted to assess whether changes
in study cohorts would have changed conclusions.
Results: Sixty-one studies were included in the two reviews. Thirty-five studies were present in just one review; of these,
twenty were identified and excluded by the parallel review.
Omissions were due to: review scope (9 studies, 26 %), outcomes of interest not measured (8 studies, 23 %), exclusion of
reports with inadequate reporting (6 studies, 17 %), mixed or unclear reasons (3 studies, 8 %), search strategies concerning
filters, tagging, and keywords (3 studies, 8 %), search strategies regarding sources (PUBMED not searched) (2 studies, 6 %);
discordant interpretation of same eligibility criteria (2 studies, 6 %), and non-identification due to non-specific study topic
(2 studies, 6 %). Review conclusions differed, but were likely due to differences in synthesis methods, not differences in
study cohorts.
Conclusions: The process of study identification for SRs is part art and part science. While some differences are due to
differences in review scope, outcomes measured, or reporting practices, others are caused by search methods or
discrepancies in reviewer interpretations. Different study cohorts may or may not be a cause of differing SR results.
Completeness of SR study cohorts could be enhanced by 1 – independent identification of studies by at least two
reviewers, as recommended by recent guidelines, 2 - searching PUBMED with free-text keywords in addition to MEDLINE
to identify recent studies, and 3 - Using validated search filters.
Keywords: Systematic reviews, Meta-analysis, Evidence-based decision making, Electronic searching, Tobacco smoke
exposure, Tobacco control
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Systematic reviews (SRs) of the professional literature,
sometimes termed the “platinum” standard of evidence
[1], form the foundation for clinical guidelines and
evidence-based health policy, thus shaping the policy
agenda in medicine and public health [2, 3]. Contrary to
narrative reviews, which may be biased due to non-
systematic procedures for identifying original studies,
SRs enjoy high credibility. Despite their popularity in re-
cent years, enormous importance, and clear advantages
over traditional reviews, it is not easy to validate the re-
sults of a given SR: there is simply no “gold standard”
with which to compare the results. The scientific
community has approached this issue by 1 – creating
reporting standards [4–6]; 2 – developing tools to
validate SR quality [7] and risk of bias [8]; and 3 –
applying those standards and tools to published SRs
[4, 9–16]. A fourth approach, made possible by the
proliferation of published SRs on similar topics, is
based on empirical comparisons of SR methods, re-
sults, and conclusions [17–25].
Performing a systematic review is a complex task, and
searching for studies is one of the most difficult aspects.
An early version of the Cochrane Handbook [Cochrane
Handbook 2006, Section 5.3, p.76] [26], stated: “Identify-
ing all relevant studies … is… largely what distinguishes
a systematic review from a traditional narrative review.”
Experience in conducting SRs over the years has shown
that identifying all relevant studies was too ambitious;
consequently, in recent versions of the handbook, that
statement has been modified to read: “Systematic re-
views of interventions require a thorough, objective and
reproducible search of a range of sources to identify as
many relevant studies as possible (within resource
limits).” [27] (Section 6.1.1.2).
Indeed, identifying the entire set of relevant published
studies is challenging at best, and may not be possible.
In comparing SRs in 1996, Cook [19] found “incomplete
identification of relevant studies”. In 17 review sets ad-
dressing the same topics, Linde found that the set of in-
cluded primary studies varied by more than 50 % in 10
review sets [21]. Campbell reported differences in search
strategies [18]. Rosen et al. comparing reviews per-
formed by the US Community Guide and Cochrane on
tobacco control, found that the US Community Guide
did not locate (for reasons other than publication date),
on average, 66.1 % of original studies included in the
comparative Cochrane reviews, whereas Cochrane did
not locate (for reasons other than publication date), on
average, 43.5 % of Guide studies [22]. Goodyear [28]
compared 2 reviews on a similar topic, and found “im-
perfectly overlapping studies.” Ford [25], in his study of
8 meta-analyses on similar topics, found that 6 of the 8
meta-analyses missed relevant studies, and that 5 of 8meta-analysis included studies which were ineligible ac-
cording to the review’s stated inclusion criteria. We are
unaware of any previous studies comparing similar sys-
tematic reviews which focused on detailed search proce-
dures as well as selection procedures.
On March 24th, 2014, a systematic review and meta-
analysis of interventions aimed at protecting children
from tobacco smoke exposure was published [29]. One
author of this paper (LJR) was the lead author on that
paper, and the other author (RS) had performed the lit-
erature search. The following week, on March 31, 2014,
the Cochrane Collaboration published its third issue of
the year, which included a review on the same topic con-
ducted by Baxi et al. [30] While many of the studies
were common to both reviews, some studies appeared in
just one review. We attempted to discover, for topics
which were common to both reviews, which studies
were present in only one review, and find an explanation
for the omission in the parallel review. Our primary goal
was to identify flaws in the process of article identifica-
tion in this set of two reviews, and use that information
to improve future study identification processes. We also
considered whether identifying or including omitted
studies would have changed the results or conclusions of
the reviews.
Methods
In order to compare the sets of studies included in two
reviews published almost simultaneously on the topic of
child protection from tobacco smoke exposure (Rosen
2014 [29] and Baxi 2014 [30]), we did the following: 1 -
Compared inclusion and exclusion criteria in the two re-
views; 2 - Compared the search processes in the two re-
views; 3 - Identified which studies were included in just
one review; and 4 – Attempted to discover reasons for
omission from one review. For studies explicitly ex-
cluded by one review, we explored why those studies
were included in just one review. For studies which were
not identified by one review, we examined possible rea-
sons for non-identification. This included carefully
examining records from databases to check dates of
entry into the database, and keywords associated with
the record.
Information on study identification, inclusion, and ex-
clusion were obtained from the published reviews, and
from correspondence with the lead author of the
Cochrane review. Baxi referred to single or multiple cita-
tions, while Rosen referred to a single citation for each
study. In our comparison, we used a single citation if
there was one. We address issues stemming from mul-
tiple citations as necessary.
We compared the following aspects of the two re-
views: methods of data synthesis; quality of reviews
(AMSTAR [7]); key results and conclusions; discordancy
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(GRADE) [31]. We also and considered whether identifi-
cation and/or inclusion of omitted studies would have
changed conclusions.
Results
Inclusion and exclusion criteria
The differences and similarities between the inclusion
criteria are presented in Table 1.
Both study titles focused on child tobacco smoke
exposure (TSE) reduction. The definition of objectives
as defined in the abstracts of the two reviews was es-
sentially identical. In the text, Baxi specified objec-
tives and outcomes which were broader than Rosen’s:
she included parental/caretaker cessation and child
health measures in addition to child TSE reduction.
The acceptable interventions, study designs, and com-
parisons were identical in both reviews. Baxi’s accept-
able population was broader: Rosen included parents
of children aged 0-6, while Baxi included parents,
caretakers, and educators of children 0–12. Rosen,
but not Baxi, restricted eligibility to studies with
follow-up of at least 1 month.
Search processes
Baxi’s search strategy can be found at: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD001746.pub3/
full#CD001746-sec1-0011. Rosen’s search strategy can
be found in Additional file 1. The search process used
by each study is summarized in Table 2. Baxi’s review
was the third update of previous reviews on this topic.
The updated search, most recently conducted in Sept.
2013, was conducted by a librarian and a Cochrane trial
search coordinator. Rosen’s review was the second in a
series of meta-analyses; the first of which focused on
parental cessation [32, 33]. Rosen’s electronic search was
conducted by a librarian (RS), most recently in early
October, 2013.
Both Baxi and Rosen reported their overall search strat-
egies, and both gave reasons for excluded studies. Rosen
presented the flow chart recommended by PRISMA re-
garding number of records retrieved, scanned, and num-
ber of full-text articles read.
Both Baxi and Rosen searched Ovid MEDLINE, but
only Rosen searched also Ovid MEDLINE In-Process
& Other Non-Indexed Citations. Both used subject
headings for their main subject, Rosen also used free
text terms.
Both searched EMBASE, and PsychInfo. Baxi, but
not Rosen, systematically reviewed reference lists of
all included studies, searched the grey literature, and
searched CINAHL, ERIC, CENTRAL and Cochrane
Specialised Group Register. Rosen, but not Baxi,
searched WoS and added Pubmed to identify articlesnot included in any segment of Ovid MEDLINE.
Baxi used Cochrane’s highly sensitive filter for study
design, while Rosen used a non-validated specific fil-
ter. Both authors used published and unpublished
information obtained from the authors.Study identification and exclusion
All studies identified
Sixty-one studies were included in the two reviews. Baxi in-
cluded 57 studies, and Rosen included 30 studies. Twenty-
six studies were included in both reviews (Cochrane Identi-
fier: Abdullah 2005, Baheiraei 2011, Butz 2011, Chan
2006a, Chellini 2013, Conway 2004, Eriksen 1996, Fossum
2004, Greenberg 1994, Groner 2000, Halterman 2011,
Hovell 2000, Hovell 2002, Hovell 2009, Irvine 1999, Krieger
2005, McIntosh 1994, Prokhorov 2013, Severson 1997,
Stotts 2012 2013, Tyc 2013, Wakefield 2002, Wilson 2001,
Wilson 2011, Yilmaz 2006, Zakarian 2004). The Cochrane
review provided multiple citations for many of the studies.
One study which was included in both reviews was based
on information from different reports [34, 35].
The thirty-five studies which were included in just one
review are listed in Table 3 [36–70]. Figure 1 summa-
rizes the status and reasons for omission of all studies.
Of the 35 studies, twenty were identified by the paral-
lel review and excluded [37–41, 43, 45, 48, 50–54, 58–
61, 66, 68, 69]. All but one of these [53] were found and
excluded by Rosen.
Studies identified and excluded
Baxi identified and excluded one study (Lanphear [53])
at the abstract stage, on the basis of goals. The stated
reason for the exclusion was that reducing child envir-
onmental tobacco smoke exposure was not defined as a
primary objective (Personal communication, July 31,
2014). However, in the Introduction, Lanphear included
secondhand smoke exposure reduction as an explicit
goal. The reason for omission was categorized as “Dis-
cordant interpretation of same eligibility criteria.” The
remaining 19 studies were excluded by Rosen. One study
was excluded at the title stage (Ekerbicer [43]), due to
age of children. Three studies were excluded at the ab-
stract stage; one due to age (Culp [40]), one due to out-
comes and goals (maternal tobacco consumption)
(Nuesslein [54]), and one due to outcomes (Ralston
2013 [58]). Of the 15 studies which were excluded by
Rosen at the stage of full-text reading, 6 were excluded
because there were no relevant outcomes. (Chan [38],
Curry [41], Emmons [45], Hughes [50], Ralston 2008
[58], Winickoff [68]) Six studies were excluded because
data necessary for meta-analysis review was missing [39,
48, 51, 52, 61, 69]. All but one of these [61] were missing
means, and/or standard deviations, and/or sample sizes.
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of the reports was based on discordant interpretation for
the same eligibility criteria (study design) [37]. This oc-
curred even though both reviewers had identical inclu-
sion criteria for study design. The Borrelli study design
involved randomization to 2 active intervention groups.
Rosen excluded the study because it was unclear which
group to include as the “intervention” and which to in-
clude as the “control”.
Rosen excluded one paper [66] because it was a
follow-up study of a paper by Hovell 1994 [71] which
she was planning to include. After the initial exclusion
decision on the Wahlgren paper was made, the Hovell
trial was excluded because data for the meta-analysis
were unavailable from the authors. Had the Wahlgren
paper been reconsidered (as it should have been); it
would have been rejected because the control group was
exposed to intervention materials at the close of the ini-
tial intervention period, leading to the probability that
the control group was contaminated by exposure to con-
trol materials. This was categorized as “mixed” reason
for omission.
The Ratner paper [60] was excluded by Rosen due
to lack of a control group. The paper described a
small, uncontrolled observational study which was a
follow-up of a randomized trial. That study was in-
cluded by Baxi, who cited 5 papers relating to that
trial, which focused on preventing smoking relapse
post-partum. The additional reports were not found
by, or relevant to, Rosen’s review. This could not be
clearly classified as a discrepancy between reviewers,
as it is possible that Baxi primarily utilized data from
the other quoted studies. Therefore the reason for
omission was categorized as “Mixed”.
Studies not identified
Fourteen studies were not identified by the parallel
review [36, 42, 44, 46, 47, 49, 55–57, 62, 64, 65, 67, 70].
Two of these were excluded automatically by Rosen’s
age filter [44, 70]. Two studies [49, 62] were not found
by Baxi because of her search methodology: she did not
search PUBMED, and these two publications were avail-
able in PUBMED, but not MEDLINE, at the time of
search.
The following three articles, which appeared in Baxi’s
review, but were not identified by Rosen’s electronic
search, were not identified due to issues with filters,
index terms or free-text search terms:
 The Patel study [55] was in EMBASE at the time of
Rosen’s search. Though the Abstract and Methods
sections stated that participants had been
randomized to intervention or control groups, and
the study design was therefore a randomizedcontrolled trial (RCT), there was no mention of
RCT in the Abstract or title. Rather, the authors
used the term “prospective follow-up Pilot study” in
the Methods Section of the article. The article was
not indexed as an RCT.
 Rosen’s search filter relied on correct indexing
(“randomized controlled trial” or “controlled clinical
trial” as Emtree terms). Baxi found Patel in the
Cochrane register, where it had been identified
through a periodic search of EMBASE.
 The Vineis study [65] was missed by Rosen’s
MEDLINE search. Vinies called his study a
“population-based trial” in the Abstract, and a “non-
randomized experimental design” in the Methods
section. Participants were assigned to intervention
and control groups in a non-random manner. This
was therefore a controlled trial, but was not termed
as such by the authors.
 The Pulley study [57], which was in PUBMED but
not indexed in MEDLINE at the time of the search,
was missed because neither the title nor the abstract
mentioned that it was an RCT. Rather, it was
described a “longitudinal, quasi-experimental design”
in both the Abstract and the Methods section. Con-
firmation that this was an RCT is in the Methods
section, in the statement: “Mother-infant pairs were
randomly assigned to the either the control or inter-
vention group (p.31). In addition, the status of this
record in PUBMED is “Pubmed-not-Medline” which
means that this record is not indexed.
Five studies which were included by Baxi but not identi-
fied by Rosen addressed topics not included in Rosen’s re-
view (prevention of postpartum relapse to smoking [46, 47,
56, 64]; cessation among young mothers [42]). Two add-
itional studies which were included by Baxi but not identi-
fied by Rosen [36, 67], addressed very general health
outcomes, without a stated objective regarding protection
of children from tobacco smoke. One of those papers [36]
was identified during a search for papers for a review on
another topic. Another was identified in previous versions
of the Cochrane review, (Personal correspondence, Ruchi
Baxi, 31 July 2014) but not through an electronic search for
this review.
Duplicate / unclear study identification
One study which was included by Rosen but not by Baxi
[63] may have been identified and excluded prior to
reading the full-text article, but it is unclear (Personal
correspondence, Baxi, July 31, 2014).
Another study was included in both reviews, but based
on two different reports [34, 35]. Baxi included a confer-
ence report [34] which Rosen did not locate, as she did not
search grey literature sources. Rosen included a published
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not search PUBMED, and at the time of search the paper
was available on PUBMED but not on MEDLINE.
Summary of reasons for omissions
We found that omissions were attributable to: review scope
(9 studies, 26 %) [40, 42–44, 46, 47, 56, 64, 70], outcomes
of interest not measured (8 studies, 23 %) [38, 41, 45, 50,
54, 58, 59, 68], exclusion of reports with inadequate report-
ing (6 studies, 17 %) [39, 48, 51, 52, 61, 69], mixed or un-
clear reasons (3 studies, 8 %) [60, 63, 66], search strategies
concerning filters, tagging, and keywords (3 studies, 8 %)
[55, 57, 65], search strategies regarding sources: PUBMED
not searched (2 studies, 6 %) [49, 62]; discordant interpret-
ation of same eligibility criteria (2 studies, 6 %) [37, 53];
and non-identification due to non-specific study topic.
(2 studies, 6 %) [36, 67].
Comparison of the two reviews
a. Data synthesis
Data were synthesized differently in the two reviews. Baxi
used a narrative approach to synthesizing the reviews, not-
ing that this was because of heterogeneity of methodologies
and outcome measures; she used the “head-counting” [72]
approach to determining how many studies showed statisti-
cally significant results. Rosen took a meta-analytic ap-
proach. She used the random effects model due to
heterogeneity between studies, and standardization to over-
come the problem of heterogeneity between outcome mea-
sures. Using a narrative approach, as was done by Baxi, and
using random effects models, as was done by Rosen, are
both considered reasonable solutions to the problem of het-
erogeneity [73].
b. Assessment of quality using AMSTAR
The AMSTAR [7, 73] checklist was used to assess
quality of the two SRs. Baxi’s review received a perfect
score (11/11). Rosen received a score of 9/11. She lost
one point because she did not have a published protocol
and one point because she did not search the grey
literature.
c. Comparisons of key results and conclusions
Review conclusions differed for both primary and sub-
group analyses.
Primary analysis
Baxi: The Results Section of the Abstract reported
that “In only 14 of the 57 studies was there astatistically significant intervention effect for child ETS
exposure.” In the Authors’ Conclusions Section of the
Plain Language Summary, Baxi interpreted this and her
other statements to mean that “Although several
interventions …. have been used to try to reduce
children’s tobacco smoke exposure, their effectiveness
has not been clearly demonstrated.”
Rosen: Rosen’s results showed that interventions
demonstrated some benefit to intervention
participants at follow-up for parentally-reported ex-
posure or protection (PREP outcome) (relative risk
1.12, p < .0001) and number of cigarettes smoked
around children by parents at follow-up (P = .03).
There was a non-significant trend towards benefit
to interventions as measured by biomarkers ((RD
20.05, CI 20.13 to 0.03, P = .20). The summary
statement in the Conclusions section of the abstract
stated: “Interventions to prevent child TSE are
moderately beneficial at the individual level.”
Using Moja’s [16] approach for discordant findings,
Rosen’s review could be classified as “efficacious” be-
cause there was a statistically significant benefit to the
intervention groups when using the parentally-reported
measures, or as “mixed” as biochemical measures did
not show a statistically significant effect.
The two SRs would probably be considered discordant
by Moja’s criteria.
Subgroup analysis
Baxi: Baxi found that “The review was unable to
determine if any one intervention reduced parental
smoking and child exposure more effectively than
others, although seven studies were identified that
reported intensive counselling or motivational
interviewing provided in clinical settings was effective.”
In the Conclusions Section of the text, she stated that
“no intervention or setting was clearly more efficacious,
and that intensive interventions for parents showed
limited success.”
Rosen: In an exploratory subgroup analysis, Rosen
found that “Most subgroups showed significant, albeit
small, benefit to the interventions.”
Neither author had a very clear statement, as Baxi’s
was ambiguous, and Rosen’s was based on exploratory
analyses.
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GRADE. The GRADE system [31] provides guidance
in how to use evidence to make recommendations.
There are four possible recommendations: strong
against, strong for, weak against, and weak for.
Given the positive finding of Rosen on parentally-
reported measures, and non-significant finding on
biochemical measures, it is unclear what the classifi-
cation would be. Baxi’s results might result in a
“research only” recommendation.
e. Would identification and/or inclusion of studies
omitted have changed review conclusions?
It is not possible to give a definitive answer to this
question, but we tried to assess the possible impact of
the unidentified studies.
 ROSEN: Of the studies not identified by Rosen,
three would have been excluded on the basis of
inclusion criteria (age: Elder [44], Zhang [70],
minimum follow-up: Pulley [57]), five on the basis of
goals (postpartum relapse: French [46], Hannover
[47], Phillips [56], Van’t Hopf [64], cessation of
young mothers Davis [42]), one due to broad goals
with no measured outcomes of interest (Wiggens
[67]), two due to poor reporting (no reports on
relevant outcomes at study end for all randomized
participants (Vineis [65], Patel [55]). One study
(Armstrong [36]) had general goals and included
relevant data; whether it would have been included
would have required a judgement call. Therefore,
the maximum difference which could have occurred
would have been the addition of one study to one of
the four endpoints examined by Rosen. The meta-
analysis was rerun, with nearly identical results
(RR = 1.13, p < .0001). Therefore, identification of
additional studies would not have affected review
results.
 BAXI: Two studies (Huang [49] and Streja [62])
included by Rosen were not identified by Baxi, an
additional one (Teach [63]) may or may not have
been identified, and one more (Lanphear [53]) may
have been mistakenly omitted. Baxi (personal
communication, July 31, 2014) thought that of these
studies, only Streja [62] would have been included.
It is not clear how this would have been handled by
two Cochrane reviewers. The maximum difference
in results would come from adding all four studies
to the review. Two of the studies, Huang [49] and
Teach [63], showed beneficial and statistically
significant benefit to the intervention on parentally-
reported child exposure or protection (PREP) at
study end. Streja [62] did not show a statistically
significant benefit on change in PREP. Lanphear [53]found no differences between intervention and con-
trol groups on child biomarkers at study end or on
numbers of cigarettes smoked around the house.
If the Steja study was included in the review, then 14/
58 instead of 14/57 studies would have been shown to
be beneficial. The addition of all 4 studies- the max-
imum change - would have resulted in statistically-
proven benefit in 16/61 (26.2 %) of studies instead of 14/
57 studies (24.6 %). This would not have changed the
main conclusions of the review.
Discussion
The process of identifying studies for inclusion in a sys-
tematic review is complex, and involves both electronic
and human aspects. Of the sixty-one studies included in
the two reviews analyzed in this report, nearly 60 % (35/
61) were present in just one review. Of these, over half
(20/35), were identified and excluded by the parallel re-
view, while over 40 % were not identified. Most omis-
sions were due to differences in review scope (as
expressed in inclusion criteria and search filters), meas-
urement of outcomes, differing requirements for quanti-
tative data, and search issues, including how and which
sources were searched. A minority of omissions (2) re-
sulted from discordant reviewer interpretations of identi-
cal inclusion criteria. We explore these issues below.
Review scope
Review scope was an important factor in creating the
different study cohorts in these reviews, as expressed in
search strategies and inclusion criteria. It has been noted
that differing inclusion criteria is one of the factors
which contributes to SR discordance [15]. In our com-
parison, omission of studies from one review was some-
times due to differences in inclusion criteria, which were
much broader in Baxi’s review than in Rosen’s review.
Differences in age criteria (up to age 12 in Rosen, and
up to age 18 in Baxi) caused the exclusion of two studies
[40, 43] and were likely responsible for the non-
identification of two additional studies [44, 70]. The
scope of the review was like also responsible for the
non-identification of an additional 5 studies [42, 46, 47,
56, 64]. which would have been excluded from Rosen’s
review.
Exclusions due to measurement and reporting of
outcomes
The Cochrane MECIR best practice guidelines, state that
neither outcomes nor poor reporting should be used as
an exclusion criteria. Inclusion of these studies in the
review, even if some studies won’t be used in the meta-
analysis, is desirable because it allows readers to judge
whether outcome reporting bias exists. The MECIR
Table 1 Eligibility Criteria for inclusion of original studies in systematic reviews by Baxi and Rosen
Criteria Baxi Rosen
Title Family and carer control programs for reducing children’s
exposure to environmental tobacco smoke




“To determine the effectiveness of interventions aiming to reduce
exposure of children to ETS.” (p.1)




“To evaluate the effectiveness of programmes for both the
prevention and cessation of smoking by those who interact with
children, and teachers, and the effect on health outcomes in
infants, toddlers and young children; 2) To examine and detail the
indicators of intervention processes and to identify outcomes of
importance to those involved in the care of children and young
people.” (Objectives, p.3-4) Under Types of Interventions, she
addressed aims again, with the statement: “We included studies
where the primary aim was to reduce children’s exposure to ETS
(thereby preventing adverse health outcomes), but where secondary
outcomes included reduction or cessation of familial/parental/carer
smoking, or changes in infant and child health measures. We also
included studies where the primary outcome was reduction or
cessation of familial/parental/carer smoking resulting in reduced
exposure for children.” (p.4).
“original studies evaluating interventions aimed at protecting
children from TSE.” (p.699)
Participants Parents, caretakers, or educators of children 0-12 years. Parents of children 0-6 years.
Interventions No restrictions on type of intervention No restrictions on type of intervention
Comparisons Differences between intervention and control groups at end of
study, or compared changes in outcomes from beginning to end of
study, between intervention and control groups.
Differences between intervention and control groups at end of
study, or compared changes in outcomes from beginning to
end of study, between intervention and control groups.
Outcomes Child exposure to ETS via biomarkers and/or parental reports, child
illness, child use of health services, parental smoking behavior
(including home smoking bans, cessation, change, and initiation),
and cost and cost-effectiveness.
Parentally-reported exposure or protection (PREP); parentally-
reported number of cigarettes smoked around child (means,
standard deviations, n’s required), and biomarkers of child
exposure (means, standard deviations, n’s required).
Study
design
Controlled trials, with or without randomization. Controlled trials, with or without randomization.
Time No restrictions Minimum 1-month follow-up
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ies on the basis of outcomes, care should be taken to as-
certain that relevant outcomes are not available because
they have not been measured rather than simply not
reported.”
Missing relevant outcomes caused the exclusion of
8 studies by Rosen [38, 41, 45, 50, 54, 58, 59, 68].
Other studies not included in this comparison were
excluded from both Rosen and Baxi due to outcomes.Table 2 Comparison of search elements used in two systematic rev
Search element Baxi
Search done by a professional librarian Yes
Use of results of previous searches Yes
Checking reference lists of included studies Yes
Enquiries for other relevant studies Yes
Bibliographic Databases Searched MEDL
PSYC
Coch
Use of subject headings in search strategy Yes
Use of free text to locate relevant non-indexed reports No
Type of filter for study design Broad
Use of grey literature YesThe absence of key data from six studies [39, 48, 51,
52, 61, 69] caused the exclusion of those studies from
Rosen’s review, which employed a meta-analytic
approach, but not from Baxi’s review, which used a
narrative approach to synthesizing the data. Rosen
differentiated between studies which didn’t collect
outcomes (“no relevant outcomes reported”) and
studies which didn’t report on relevant outcomes















Table 3 List of all studies included in one of the two reviews





Included Not identified Non-specific study topic Not identified: Non-specific study topic
Borelli 2010 Included Identified &
Excluded (FT)
No true control group Discordant interpretation of same eligibility criteria
Chan 2005 Included Identified &
Excluded (FT)





Data unavailable Systematic review methodology: Exclude reports
with inadequate reporting
Culp 2007 Included Identified &
Excluded (ABS)
Population (pregnant) Review scope
Curry 2003 Included Identified &
Excluded (FT)
Outcomes Outcomes not measured





Population (age) Review scope





Outcomes Outcomes not measured
French 2007 Included Not identified Review scope Review scope
Hannover
2009
Included Not identified Review scope Review scope
Herbert 2011 Included Identified &
Excluded (FT)
Data unavailable Systematic review methodology: Exclude reports
with inadequate reporting
Huang 2013 Not identified Included Search strategy: Source (PUBMED not
searched)
Not identified: Search strategy: Source (PUBMED
not searched)
Hughes 1991 Included Identified &
Excluded (FT)
Outcomes Outcomes not measured
Kallio 2006 Included Identified &
Excluded (FT)
Data unavailable Systematic review methodology: Exclude reports
with inadequate reporting
Kimata 2004 Included Identified &
Excluded (FT)











Outcomes Outcomes not measured
Patel 2012 Included Not identified Search strategy - Excluded by filter due
to incorrect tagging
Not identified: Search strategy: Filters, tagging,
keywords
Philips 2012 Included Not identified Review scope Review scope
Pulley 2002 Included Not identified Search strategy: inadequate reporting
by authors
Not identified: Search strategy: Filters, tagging,
keywords
Ralston 2008 Included Identified &
Excluded (FT)
Outcomes Outcomes not measured
Ralston 2013 Included Identified &
Excluded (ABS)
Outcomes Outcomes not measured
Ratner 2001 Included Identified and
Excluded (FT)





Data unavailable Systematic review methodology: Exclude reports
with inadequate reporting
Streja 2012 Not identified Included Search strategy: Source (PUBMED not
searched)
Not identified: Search strategy: Source (PUBMED
not searched)
Teach 2006 Not included or
excluded
Included Unclear status Mixed/Unclear
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Table 3 List of all studies included in one of the two reviews (Continued)
Van't Hof
2000
Included Not identified Review scope Review scope
Vineis 1993 Included Not identified Search strategy - Excluded by filter due
to incorrect tagging



















Data unavailable Systematic review methodology: Exclude reports
with inadequate reporting
Zhang 1993 Included Not identified Search strategy: Search limits (age filter) Review scope
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PUBMED
Though MEDLINE and PUBMED are sometimes
thought to be identical, they are not: According to the
U.S. National Library of Medicine, as of May 2014,
MEDLINE held over 21 million records, while PUBMED
had over 23 million references, including all MEDLINE
records and additional records [74]. Some of the 2 mil-
lion additional references refer to very recent publica-
tions which are not yet available in MEDLINE, while
others refer to articles in journals not covered by MED-
LINE. The reason why articles may appear in PUBMED
earlier than MEDLINE is a function of the process of
article entry into the two databases. When an article is
first published electronically, publishers can upload it
immediately to PUBMED, prior to print publication. The
record receives the status of "Publisher" in PUBMED re-
cords, and at this stage it appears in PUBMED only, andReview scope (9 studies)
26%
Not identified. Search strategy:
Filters, indexing, keywords (3
studies)
8%
Not identified. Search strategy:
Sources (Pubmed) (2 studies)
6%
Not identified. Non-specific 
topic of study (2 studies)
6%
Fig. 1 Reasons for omission of studies from one of two revewsdoes not yet appear in any segment of MEDLINE [75].
The record goes through two additional stages before it
fully enters into MEDLINE: first, the record receives a
status of "In-Data Review," during which time the article
data are validated; then, the record receives a status of
"In Process" until MESH index terms are assigned. At
this stage the record can also be found by searching
Ovid MEDLINE In-Process database using free-text
keywords.
This indexing process accounts for the time lag
between appearance of a record in PUBMED and its
appearance in MEDLINE. The time lag can be consider-
able. Duffy [76] investigated the time lags of two studies
and found out that one study included in a SR was
available in MEDLINE a month after it appeared in
PUBMED, while a second study that was included in an
SR did not appear in MEDLINE until six months after it
appeared in PUBMED.Systematic Review
Methodology: Exclude reports






same eligibility criteria (2
studies)
6%
Outcomes not measured (8
studies)
23%
Table 4 Recommendations for enhancing complete
identification of relevant studies for systematic reviews
1. This study provides empirical support for recommendations by recent
systematic review guidelines, which state that two reviewers should
independently identify studies.
2. Reviewers should search pubmed with free-text terms to identify
recent studies, in addition to searching medline, due to the lag-time
between article publication and entry to medline.
3. When using a study design as part of the search strategy, validated
search filters are preferable
Rosen and Suhami BMC Medical Research Methodology  (2016) 16:24 Page 10 of 13Three recent reports were missed by Baxi [35, 49, 62],
who searched MEDLINE but not PUBMED, but were
found by Rosen through her PUBMED search with free-
text search terms. One of these studies [34] was included in
abstract form in Baxi’s review. The time period for Stotts
2013 [35] to move from "Publisher" status to "In-Process"
and enter MEDLINE was five months, the time period for
Huang 2013 [49] was more than 8 months. Streja [62] en-
tered MEDLINE only a year and a half after being available
in PUBMED.Electronic search issue 2: Indication of study design in
title or abstract
In bibliographic databases such as MEDLINE,
PUBMED and Embase, searches are done on the title,
abstract and subject headings, not on the full-text of
the article. When a record is not indexed, the ability
to filter for study design is dependent upon correct
reporting in the title and/or abstract of the report.
One study [57], a “pubmed-not-medline” record, was
missed because neither the title nor the abstract indi-
cated that it was an RCT.Electronic search issue 3: Index terms, free-text terms,
and search filters
Index terms are assigned to articles in MEDLINE
(MESH), EMBASE (EMTREE), and other databases. They
describe the subject of the study and other parameters
such as study design. Study design can serve as a filter to
the search when a SR is limited to a certain study design,
such as RCT. In this study, two reports were missed by
Rosen due to problems with index terms [55, 65].
The indexing process is a complex task in which judg-
ment calls by indexers play an important role. Indexing
problems are not uncommon. Crumley [77] indicates that
"For electronic databases, the reason cited most often
(67 %) for missed studies was inadequate or inappropriate
indexing". Our findings suggest that inadequate indexing is
due at least in part to author failure to include study design
explicitly in the title or abstract. Both the Cochrane Hand-
book [27] and the CONSORT reporting guidelines [78] re-
quire reporting of study design in the title or abstract. Ourfindings, and information about missed studies in the litera-
ture, support these recommendations.
For this reason, Cochrane Handbook and other guide-
lines also recommend using free-text terms in addition
to index terms for the search process.
In order to help researchers combine their subject
search terms with appropriate study design, methodo-
logical search filters were developed and tested for their
quality. Cochrane developed filters for RCT in MED-
LINE, (http://handbook.cochrane.org/ Section 6.4.11)
but other organizations developed their own. For example,
SIGN, a Scottish guidelines body, develops in-house filters
and adapts other organizations' filters according to its
needs. SIGN states that its filters "may provide less sensitive
searches than used by other systematic reviewers such as
The Cochrane Collaboration, but enable the retrieval of
medical studies that are most likely to match SIGN's meth-
odological criteria." (http://www.sign.ac.uk/methodology/
filters.html#random) BMJ Clinical Evidence presents a
different filter for RCT (http://clinicalevidence.bmj.com/x/
set/static/ebm/learn/665076.html). CADTH, a Canadian
organization that publishes evidence-based medicine re-
search, also develops and maintains its own search filters
(https://www.cadth.ca/resources/finding-evidence/strings-
attached-cadths-database-search-filters).
Over the years, numerous filters have been developed,
and one study compared between as many as 38 RCT filters
for MEDLINE [79]. These filters differ in the way and the
time they were developed, tested and validated, and their
performance is not always well reported [80].
Best choice of filter is difficult, and a clear guidance or
tool to help researchers in this complex task is lacking.
A recent study suggested that filter performance be pre-
sented as a forest plot, to allow visualization by re-
viewers of benefits [81]. Though there is no consensus
on how to choose a filter, using a validated filter is
recommended.
The ubiquitous role of judgment calls
Even with clearly defined inclusion and exclusion criteria,
and an appropriate search strategy, reviewers must regu-
larly make judgment calls about whether to include or ex-
clude a study. This occurs at all stages of the process of
study identification: at the level of scanning records, at the
level of reading abstracts, and at the level of reading full-
text articles. It has previously been suggested that bias can
be “injected” into meta-analysis at the stages of finding
studies, selection of studies for inclusion, and data extrac-
tion [82].
In our comparison, two identified studies were omitted
on the basis of differences in judgments between re-
viewers [37, 53]. We did not find reason to suspect bias.
Rather, these examples illustrate the complexity of
judgement calls.
Rosen and Suhami BMC Medical Research Methodology  (2016) 16:24 Page 11 of 13The responsibility for making reasonable decisions falls
on different individuals, at different points in the process.
Errors might arise due to the creation of the search strat-
egy, which may be under the control of one or more indi-
viduals; by authors of original reports, as they decide how
to write the report and which data to include; by database
indexers, and by reviewers.
Possible effects of missing studies on review results and
conclusions
There are several possible effects of omitting studies
from systematic reviews. First, such omissions reduce
usefulness, because the review is incomplete. Second,
such omissions could affect conclusions, particularly if
many relevant studies were missed. Even a small number
of missed studies – even if the results are in the same
direction as the results of the found studies - may affect
conclusions if the study estimates are synthesized using
a meta-analytic approach: fewer studies result in a loss
of power to detect a true effect if it exists. Third, such
omissions may suggest bias in the results, either
intentional (See: Goodyear-Smith [28]) or unintentional.
The smaller bias in SRs with more comprehensive
search strategies has been previously noted [15].
Would the review results have changed with the
identification of or inclusion of omitted studies?
Our analyses showed that identification and inclusion of
omitted studies would likely not have changed results of
either review. The most likely reason for discrepant re-
sults is due to differences in summary methods. Differ-
ences in scope may have also played a role, though that
is difficult to show, as the summary methods differed. It
is well known that one of the advantages of meta-
analytic synthesis over narrative synthesis is that small
effects may be detected and quantified. The heterogen-
eity found by both reviews was dealt with in different
ways, and loss of ability to detect true effects was the
main downside of the narrative summary approach
taken by Baxi.
Strengths and limitations
This work presents a unique approach to exploring why
cohorts of original studies in similar systematic reviews
differ. Unlike the few previous comparisons which ex-
plored reasons for discrepancies in SR cohorts [19, 21,
28], this study focused on the study identification
process, and used detailed, date-specific information
from MEDLINE, PUBMED, and EMBASE to understand
why some studies were missed. The publication of two
reviews almost simultaneously on the same topic, with
similar dates of searching, allowed the comparison.
Although only two reviews were included in the com-
parison, we were able to identify several lacunae in theSR study identification and selection process. Because
our findings about omissions are general in nature, they
are likely to be problematic in some other systematic
searches as well. More work is necessary to assess how
prevalent these issues are. Adopting the comparative ap-
proach used here will likely yield information on other
stumbling blocks to identification of all relevant studies
for SRs. Combining knowledge from such comparisons
could serve as an engine for improved methods to iden-
tify relevant studies.
Recommendations
Our recommendations for enhancing complete identifi-
cation of relevant studies for systematic reviews can be
found in Table 4 below.
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